MARKET

ALXO

ALXO

Alx Oncology Holdings Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.44
-0.94
-6.54%
Opening 10:12 08/18 EDT
OPEN
14.22
PREV CLOSE
14.38
HIGH
14.35
LOW
13.43
VOLUME
141.47K
TURNOVER
1.71M
52 WEEK HIGH
81.19
52 WEEK LOW
5.82
MARKET CAP
547.64M
P/E (TTM)
-4.9359
1D
5D
1M
3M
1Y
5Y
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative™ ("Quantum Leap") today announced that ALX Oncology'...
PR Newswire · 2d ago
ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT Newswires · 2d ago
ALX Oncology And Quantum Leap Healthcare Collaborative Announce The Selection Of Evorpacept In The I-SPY-P1 TRIAL In Combination With Enhertu In Breast Cancer
ALX Oncology Holdings Inc., (“ALX Oncology”) (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare
Benzinga · 3d ago
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Col...
GlobeNewswire · 3d ago
ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu in Breast Cancer
ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu in Breast Cancer
MT Newswires · 3d ago
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation...
GlobeNewswire · 08/11 11:00
--Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating
--Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating
MT Newswires · 08/09 12:26
--Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating
--Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating
MT Newswires · 08/09 10:07
More
No Data
Learn about the latest financial forecast of ALXO. Analyze the recent business situations of Alx Oncology Holdings Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

12.50%Strong Buy
75.00%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALXO stock price target is 39.13 with a high estimate of 80.00 and a low estimate of 12.00.
High80.00
Average39.13
Low12.00
Current 13.44
EPS
Actual
Estimate
-0.65-0.49-0.32-0.16
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 106
Institutional Holdings: 37.27M
% Owned: 91.62%
Shares Outstanding: 40.75M
TypeInstitutionsShares
Increased
32
3.09M
New
10
393.27K
Decreased
34
1.64M
Sold Out
20
1.30M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.43%
Pharmaceuticals & Medical Research
-0.53%
Key Executives
Chairman/Executive Director
Corey Goodman
President/Chief Executive Officer/Director
Jaume Pons
Chief Financial Officer
Peter Garcia
Chief Accounting Officer/Vice President - Finance
Shelly Pinto
Other/Director
Sophia Randolph
Independent Director
Itziar Canamasas
Independent Director
Rekha Hemrajani
Independent Director
Jason Lettmann
Independent Director
Jack Nielsen
No Data
No Data
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. It is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), head and neck squamous cell carcinomas (HNSCC), gastric and breast cancer. Its preclinical program is focused on developing ALTA-002, which combines its signal regulatory protein alpha (SIRPa) and toll-like receptor 9 agonist antibody conjugate (TRAAC).

Webull offers kinds of ALX Oncology Holdings Inc stock information, including NASDAQ:ALXO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALXO stock methods without spending real money on the virtual paper trading platform.